NASDAQ · AGMB
Healthcare · Biotechnology
$13.94
Down-$1.02 (-6.82%)
Updated Sep 11, 2026, 5:29 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AGMB closed at $13.94 after 20 trading sessions, down 0.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $14.91 | $16.40 | $13.75 | $13.94 | 106.93K |
| Sep 9, 2026 | $14.94 | $15.70 | $14.645 | $14.96 | 72.56K |
| Sep 8, 2026 | $15.78 | $16.50 | $14.51 | $14.91 | 260.63K |
| Sep 4, 2026 | $14.83 | $15.86 | $14.53 | $15.78 | 245.27K |
| Sep 3, 2026 | $13.67 | $14.94 | $13.5856 | $14.83 | 407.96K |
| Sep 2, 2026 | $13.29 | $13.955 | $13.19 | $13.66 | 158.85K |
| Sep 1, 2026 | $12.90 | $13.99 | $12.62 | $13.54 | 241.31K |
| Aug 31, 2026 | $13.15 | $14.13 | $12.75 | $13.17 | 105.44K |
| Aug 28, 2026 | $13.84 | $14.20 | $12.84 | $13.17 | 252.92K |
| Aug 27, 2026 | $14.26 | $14.37 | $13.66 | $13.84 | 154.17K |
| Aug 26, 2026 | $14.19 | $14.60 | $13.58 | $14.28 | 243.8K |
| Aug 25, 2026 | $13.40 | $14.26 | $13.16 | $14.02 | 219.35K |
| Aug 24, 2026 | $13.21 | $13.23 | $12.755 | $12.82 | 31.65K |
| Aug 21, 2026 | $13.50 | $13.64 | $13.065 | $13.25 | 68.36K |
| Aug 20, 2026 | $13.74 | $13.85 | $13.01 | $13.43 | 92.23K |
| Aug 19, 2026 | $13.81 | $14.42 | $13.59 | $13.75 | 137.39K |
| Aug 18, 2026 | $13.62 | $13.86 | $13.42 | $13.73 | 30.87K |
| Aug 17, 2026 | $13.25 | $13.90 | $13.02 | $13.68 | 119.26K |
| Aug 14, 2026 | $14.03 | $14.03 | $13.03 | $13.22 | 41.98K |
| Aug 13, 2026 | $14.24 | $14.2867 | $13.75 | $13.945 | 241.58K |
The latest Smart Investors Daily articles mentioning AGMB.
AGMB research
Company profile and research snapshot.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | Piper Sandler | Overweight | — |
| Aug 19, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 23, 2026 | B. Riley Securities | Buy | — |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 3, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 25, 2026
Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $60.
Benzinga · Aug 19, 2026
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating.
Yahoo · Aug 10, 2026
Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026. “We are deli
Yahoo · Aug 6, 2026
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of Endoscopic Passability -- -- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b Idiopathic Pulmonary Fibrosis (IPF) Study Cohort with AGMB-447 Expected in Coming Months -- -- On Track to Initiate NOV-ERA Phase
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGMB.
